

Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity Antisense Therapeutics Limited (ASX: ANP)
ABN 41 095 060 745

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Charmaine Gittleson
Date of last notice	08 November 2021

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect														
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	-														
Date of change	28 April 2022														
No. of securities held prior to change	<table border="1" style="width: 100%; border-collapse: collapse; text-align: center;"> <thead> <tr> <th style="width: 20%;"></th> <th style="width: 40%;">Shares</th> <th style="width: 40%;">Options</th> </tr> </thead> <tbody> <tr> <td>Direct</td> <td>-</td> <td>-</td> </tr> <tr> <td>Indirect</td> <td>133,333</td> <td>-</td> </tr> <tr> <td>Total</td> <td>133,333</td> <td>-</td> </tr> </tbody> </table>				Shares	Options	Direct	-	-	Indirect	133,333	-	Total	133,333	-
	Shares	Options													
Direct	-	-													
Indirect	133,333	-													
Total	133,333	-													
Class	Fully Paid Ordinary Shares														
Number acquired	<table border="1" style="width: 100%; border-collapse: collapse; text-align: center;"> <thead> <tr> <th style="width: 20%;"></th> <th style="width: 40%;">Shares</th> <th style="width: 40%;">Options</th> </tr> </thead> <tbody> <tr> <td>Direct</td> <td>-</td> <td>-</td> </tr> <tr> <td>Indirect</td> <td>-</td> <td>6667</td> </tr> <tr> <td>Total</td> <td>-</td> <td>6,667</td> </tr> </tbody> </table>				Shares	Options	Direct	-	-	Indirect	-	6667	Total	-	6,667
	Shares	Options													
Direct	-	-													
Indirect	-	6667													
Total	-	6,667													
Number disposed	<table border="1" style="width: 100%; border-collapse: collapse; text-align: center;"> <thead> <tr> <th style="width: 20%;"></th> <th style="width: 40%;">Shares</th> <th style="width: 40%;">Options</th> </tr> </thead> <tbody> <tr> <td>Direct</td> <td>-</td> <td>-</td> </tr> <tr> <td>Indirect</td> <td>-</td> <td>-</td> </tr> <tr> <td>Total</td> <td>-</td> <td>-</td> </tr> </tbody> </table>				Shares	Options	Direct	-	-	Indirect	-	-	Total	-	-
	Shares	Options													
Direct	-	-													
Indirect	-	-													
Total	-	-													

Appendix 3Y Change of Director's Interest Notice

Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$Nil													
No. of securities held after change	<table border="1"> <thead> <tr> <th></th> <th>Shares</th> <th>Options</th> </tr> </thead> <tbody> <tr> <td>Direct</td> <td></td> <td>-</td> </tr> <tr> <td>Indirect</td> <td>133,333</td> <td>6,667</td> </tr> <tr> <td>Total</td> <td>133,333</td> <td>6,667</td> </tr> </tbody> </table>			Shares	Options	Direct		-	Indirect	133,333	6,667	Total	133,333	6,667
	Shares	Options												
Direct		-												
Indirect	133,333	6,667												
Total	133,333	6,667												
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	1 for 20 Bonus free-attaching options as per Prospectus 12 Apr 2022													

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A



The CFO Solution

29 April 2022

+ See chapter 19 for defined terms. Appendix 3Y Page 201/01/2011

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity Antisense Therapeutics Limited (ASX: ANP)
ABN 41 095 060 745

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Mark Diamond
Date of last notice	22 December 2021

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct														
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	-														
Date of change	28 April 2022														
No. of securities held prior to change	<table border="1" style="width: 100%; border-collapse: collapse; text-align: center;"> <thead> <tr> <th style="width: 30%;"></th> <th style="width: 35%;">Shares</th> <th style="width: 35%;">Options</th> </tr> </thead> <tbody> <tr> <td>Direct</td> <td>4,893,722</td> <td>14,235,274</td> </tr> <tr> <td>Indirect</td> <td>-</td> <td>-</td> </tr> <tr> <td>Total</td> <td>4,893,722</td> <td>14,235,274</td> </tr> </tbody> </table>				Shares	Options	Direct	4,893,722	14,235,274	Indirect	-	-	Total	4,893,722	14,235,274
	Shares	Options													
Direct	4,893,722	14,235,274													
Indirect	-	-													
Total	4,893,722	14,235,274													
Class	Fully Paid Ordinary Shares														
Number acquired	<table border="1" style="width: 100%; border-collapse: collapse; text-align: center;"> <thead> <tr> <th style="width: 30%;"></th> <th style="width: 35%;">Shares</th> <th style="width: 35%;">Options</th> </tr> </thead> <tbody> <tr> <td>Direct</td> <td>-</td> <td>244,687</td> </tr> <tr> <td>Indirect</td> <td>-</td> <td>-</td> </tr> <tr> <td>Total</td> <td>-</td> <td>244,687</td> </tr> </tbody> </table>				Shares	Options	Direct	-	244,687	Indirect	-	-	Total	-	244,687
	Shares	Options													
Direct	-	244,687													
Indirect	-	-													
Total	-	244,687													
Number disposed	<table border="1" style="width: 100%; border-collapse: collapse; text-align: center;"> <thead> <tr> <th style="width: 30%;"></th> <th style="width: 35%;">Shares</th> <th style="width: 35%;">Options</th> </tr> </thead> <tbody> <tr> <td>Direct</td> <td>-</td> <td>-</td> </tr> <tr> <td>Indirect</td> <td>-</td> <td>-</td> </tr> <tr> <td>Total</td> <td>-</td> <td>-</td> </tr> </tbody> </table>				Shares	Options	Direct	-	-	Indirect	-	-	Total	-	-
	Shares	Options													
Direct	-	-													
Indirect	-	-													
Total	-	-													

Appendix 3Y Change of Director's Interest Notice

Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$Nil													
No. of securities held after change	<table border="1"> <thead> <tr> <th></th> <th>Shares</th> <th>Options</th> </tr> </thead> <tbody> <tr> <td>Direct</td> <td>4,893,722</td> <td>14,479,961</td> </tr> <tr> <td>Indirect</td> <td>-</td> <td>-</td> </tr> <tr> <td>Total</td> <td>4,893,722</td> <td>14,479,961</td> </tr> </tbody> </table>			Shares	Options	Direct	4,893,722	14,479,961	Indirect	-	-	Total	4,893,722	14,479,961
	Shares	Options												
Direct	4,893,722	14,479,961												
Indirect	-	-												
Total	4,893,722	14,479,961												
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	1 for 20 Bonus free-attaching options as per Prospectus 12 Apr 2022													

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A



The CFO Solution

29 April 2022

+ See chapter 19 for defined terms. Appendix 3Y Page 201/01/2011